RecruitingPhase 2NCT06698484
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
A Phase II Open Label Single-arm Study to Evaluate Safety and Efficacy of Autologous CD19 CAR-T Cells in Patients With Relapsed/Refractory B- Non-Hodgkin Lymphoma
Sponsor
National University of Malaysia
Enrollment
20 participants
Start Date
Jun 3, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
A Phase II Open-Label Single-arm Study to Evaluate Safety and Efficacy of locally manufactured autologous CD19-directed CAR T-cells in Patients with Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) or patients not eligible for hematopoietic stem cell transplantation (HCT)
Eligibility
Min Age: 13 YearsMax Age: 75 Years
Inclusion Criteria10
- Patients with histologically confirmed diagnosed with CD19 positive B cell NHL in accordance with WHO classification
- Patients who are refractory to second-line treatment or patients who relapsed after first-line treatment with no available curative options such as autologous or allogeneic haematopoietic stem cell transplantation (HSCT) or relapse within one year of autologous HSCT
- At least one measurable lesion according to revised IWG response criteria
- Age between ≥13to ≤75 years
- Adequate organ function as defined by a creatinine clearance \>40 ml/min, serum alanine transaminase (ALT) \< 5 times the normal value, serum bilirubin \< 3 times the normal value, left ventricular ejection fraction\> 45%
- Absolute neutrophil count ≥ 1500/μl, haemoglobin level ≥ 7 g/dl, platelets ≥ 50000/μl.
- Life expectancy \>12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Female of childbearing age must have a negative pregnancy test and is on two effective contraception methods
- Male patients must use two effective contraception methods
Exclusion Criteria9
- Active central nervous system (CNS) lymphoma (detected by Imaging study or cerebrospinal fluid (CSF) analysis)
- Active cancer(other than NHL) or receiving cancer treatment
- Evidence of severe lung, heart (New York Heart Association class III/IV, arrhythmia, heart block, uncontrolled hypertension), liver, or renal failure or severe neurologic disorder
- Presence of active autoimmune disease requiring immunosuppressive therapy
- Human Immunodeficiency Virus (HIV) positivity
- Active Hepatitis B, and Hepatitis C infection
- Uncontrolled infection
- Pregnant/nursing female.
- Receiving autologous or allogeneic stem cell transplant within 12 weeks of enrolment
Interventions
DRUGCAR-T cells
2×10\^6 CAR T cells/kg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06698484
Related Trials
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT073766424 locations
The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
NCT070738332 locations